Evidence map›Paper›PMID 33614734›Full record

ArticleKidney diseases (Basel, Switzerland)2021

Infectious Complications in Patients with Primary Glomerulonephritis over 10 Years: A Single-Center Experience in Turkey.

Rezzan Eren Sadioglu, Sahin Eyupoglu, Siyar Erdogmus, Gizem Kumru Sahin, Fugen Yoruk, Sim Kutlay, Kenan Keven, Sehsuvar Erturk, Sule Sengul

Abstract read
In one paragraph

Article in Kidney diseases (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rezzan Eren SadiogluDepartment of Nephrology, Ankara University School of Medicine, Ankara, Turkey.
Sahin EyupogluDepartment of Nephrology, Ankara University School of Medicine, Ankara, Turkey.
Siyar ErdogmusDepartment of Nephrology, Ankara University School of Medicine, Ankara, Turkey.
Gizem Kumru SahinDepartment of Nephrology, Ankara University School of Medicine, Ankara, Turkey.
Fugen YorukDepartment of Infectious Disease and Clinic Microbiology, Ankara University School of Medicine, Ankara, Turkey.
Sim KutlayDepartment of Nephrology, Ankara University School of Medicine, Ankara, Turkey.
Kenan KevenDepartment of Nephrology, Ankara University School of Medicine, Ankara, Turkey.
Sehsuvar ErturkDepartment of Nephrology, Ankara University School of Medicine, Ankara, Turkey.
Sule SengulDepartment of Nephrology, Ankara University School of Medicine, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInfections can play an important role in the mortality and morbidity of patients with glomerulonephritis. However, the frequency of infectious complications in primary glomerulonephritis and their burden to the healthcare managements are not clear.

methodsWe evaluated the infectious complications in patients with biopsy-proven focal segmental glomerulosclerosis, membranous glomerulonephritis, IgA nephropathy, minimal change disease, membranoproliferative glomerulonephritis, and chronic glomerulonephritis during the last 10 years in a single center. We recorded the demographic, clinical, and laboratory characteristics; treatment modalities; infectious episodes; and infection-related mortality and morbidity of the patients.

resultsOf the patients, 154 (63.6%) received immunosuppressive treatment and 88 (34.4%) were followed up under conservative treatment. Overall, 118 infectious episodes were noted in 64 patients, with an infection rate of 0.20 per patient-year. Total infectious complications were higher in the immunosuppressive group than in the conservative group (42.1 vs. 23.3%,

conclusionsBecause of high seropositivity for CMV in Turkey, it might be a wise approach to use prophylactic antiviral drugs in patients treated with immunosuppressive treatments. Close monitoring of patients with primary glomerulonephritis, especially those treated with immunosuppressive therapy, is important for reducing infection-related morbidity and mortality.

Indexed as

GlomerulonephritisImmunosuppressionInfectionMortality

Identifiers

PMID33614734
PMCPMC7879260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.